Gabriel Pardo is a Neurology physician affiliated with Oklahoma Medical Research Foundation. OpenAlex indexes 121 publications with 2,700 citations (h-index 27); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
820 NE 15th St
Oklahoma City, OK 731044602
Telephone
405-271-6242Provider last certified this registry record 18 Oct 2020.
Clinical trials
- Skeletal Muscle Aging and Responsiveness in Aged People With MS
Sponsor: Oklahoma Medical Research Foundation
- Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis
Sponsor: Acorda Therapeutics
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
32 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- EMD Serono, Inc.Program year202598 payments$155,760openpaymentsdata.cms.gov ↗
- Genentech USA, Inc.Program year202558 payments$58,721openpaymentsdata.cms.gov ↗
- TG Therapeutics, Inc.Program year202566 payments$51,052openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
91%CD20-directed Cytolytic Antibody89.7%Ocrelizumab100%Kesimpta Pen0%Part D + Part B<11 patientsOther immunostimulants0.4%Copaxone72%Glatiramer Acetate16%Glatopa12%Part D<11 patients+ 5 more classes in this area
Nervous system
4.3%Gabapentinoids0.9%Gabapentin75%Pregabalin25%Part D≥49 patientsBenzodiazepine0.7%Clonazepam74%Alprazolam18%Diazepam8%Part D<11 patients+ 17 more classes in this area
Dermatology
3.2%Corticosteroid3.2%Methylprednisolone sodium succinate100%Part B, office-administered≥28 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Serum Proteomics Distinguish Subtypes of NMO Spectrum Disorder and MOG Antibody-Associated Disease and Highlight Effects of B-Cell Depletion
Neurology Neuroimmunology & Neuroinflammation
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Joan Merrill, MD
Oklahoma Medical Research Foundation
Judith James, MD
Oklahoma Medical Research Foundation
Eliza Chakravarty, MD
Oklahoma Medical Research Foundation
Gary Kinasewitz, MD
Oklahoma Medical Research Foundation
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”